Bone Cancer

BONE CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Study Reveals Genetic Features of Rhabdomyosarcoma That May Improve Risk Stratification

Integrating molecular profiling into current clinical stratification could improve outcomes in rhabdomyosarcoma, according to researchers.
Blood-Based Test May Establish a ‘New Paradigm’ for Cancer Screening

The test can accurately detect cancer and predict where it is located, according to researchers.
KRAS G12C Mutations in Metastatic Colorectal Cancer: Questions Remain

Dr Alan Lyss reviews studies of KRAS G12C mutations in metastatic colorectal cancer.
Racial/Ethnic Minorities Have Higher Risk of Familial-Associated Early-Onset Cancer

The study showed differences by cancer type and race/ethnicity.
Experts Review the State of Colorectal Cancer Screening in the COVID-19 Era

Two experts discuss the future of colorectal cancer screening and lessons learned during the era of COVID-19.

BONE CANCER NEWS

FDA_drug approval

Crysvita Approved for Treatment of Tumor-Induced Osteomalacia

June 23, 2020

Strontium89 Now Available for Relief of Metastatic Bone Pain

February 14, 2020

A recent article is only the latest in a series of studies drawing attention to the importance of di

FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma

May 2, 2018

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma

CTA Treatment Regimen Chart for Bone Cancer Updated

August 9, 2016

Pacritinib induced significant and sustained spleen volume reduction and symptom control in patients

Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma

July 12, 2016

Next post in Bone Cancer

Bone Cancer Treatment Regimens